
AdvaMed Position Statement Regarding Transition to National Reimbursement Codes
This AdvaMed position statement is intended to provide clarity about the transition away from the acronyms NDC/NHRIC to NRC, including rationale and implications.
This AdvaMed position statement is intended to provide clarity about the transition away from the acronyms NDC/NHRIC to NRC, including rationale and implications.
AdvaMed, the Medtech Association, today welcomed the U.S. Environmental Protection Agency (EPA) extension of 15 more days for public comment on two proposed updates to regulations governing the use of…
WASHINGTON, D.C. – Following a Congressional hearing on “Preparing for and Responding to Future Public Health Security Threats,” AdvaMed, the Medtech Association, released a statement from President and CEO Scott Whitaker echoing the…
Join NAMSA for a webinar that will highlight clinical trial site budgeting as both a risk mitigation strategy and an approach for sponsors to standardize site costs.
Each year in the U.S., ethylene oxide sterilizes 20 billion medical devices, which are critical to preventing serious, even life-threatening, infections.
AdvaMed’s medtech priorities for the 118th Congress highlight opportunities to address the most important issues facing patients and the medical technology industry today.
Get the latest on NMPA’s updated guidance for the clinical evaluation of medical devices.
Join NAMSA and the FDA as they present a webinar on the Accreditation Scheme for Conformity Assessment (ASCA) Pilot Program, a first-of-its-kind conformity assessment program created by the U.S. FDA.
Join leading authorities from FDA, academia and industry to address the latest statistical trends and issues facing medtech organizations.
These workshops will give you access to real-world case studies, tips and best practices directly from FDA and industry experts.